Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Cash from Investing Activities (2024 - 2025)

Historic Cash from Investing Activities for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $40.1 million.

  • Prelude Therapeutics' Cash from Investing Activities rose 27353.02% to $40.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $135.9 million, marking a year-over-year change of. This contributed to the annual value of $90.2 million for FY2024, which is 36032.15% up from last year.
  • Latest data reveals that Prelude Therapeutics reported Cash from Investing Activities of $40.1 million as of Q3 2025, which was up 27353.02% from $11.5 million recorded in Q2 2025.
  • In the past 5 years, Prelude Therapeutics' Cash from Investing Activities ranged from a high of $62.2 million in Q1 2025 and a low of $10.7 million during Q3 2024